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CD24 enrichment protects while its loss
increases susceptibility of juvenile
chondrocytes towards inflammation
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Abstract
Background: Diseases associated with human cartilage, including rheumatoid arthritis (RA) and osteoarthritis (OA)
have manifested age, mechanical stresses and inflammation as the leading risk factors. Although inflammatory
processes are known to be upregulated upon aging, we sought to gain a molecular understanding of how aging
affects the tissue-specific response to inflammation. In this report, we explored the role of cluster of differentiation
24 (CD24) in regulating differential inflammatory responses in juvenile and adult human chondrocytes.
Methods: Differential cell-surface CD24 expression was assessed in juvenile and adult chondrocytes along with human
induced pluripotent stem cell (hiPSC)-derived neonatal chondrocytes through gene expression and fluorescence-
activated cell sorting (FACS) analyses. Loss of function of CD24 was achieved through silencing in chondrocytes and
the effects on the response to inflammatory cues were assessed through gene expression and NFκB activity.
Results: CD24 expression in chondrocytes caused a differential response to cytokine-induced inflammation, with the
CD24high juvenile chondrocytes being resistant to IL-1ß treatment as compared to CD24low adult chondrocytes. CD24
protects from inflammatory response by reducing NFκB activation, as an acute loss of CD24 via silencing led to an
increase in NFκB activation. Moreover, the loss of CD24 in chondrocytes subsequently increased inflammatory and
catabolic gene expression both in the absence and presence of IL-1ß.
Conclusions: We have identified CD24 as a novel regulator of inflammatory response in cartilage that is altered during
development and aging and could potentially be therapeutic in RA and OA.
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Background
Cartilage degenerative diseases like rheumatoid arthritis
(RA) and osteoarthritis (OA) have inflammation, age and
obesity as causal risk factors; however, the precise molecular
mechanisms underlying these risk factors are ill-understood.
No disease-modifying drug is available for OA, while the
drugs available for RA are not equally effective in all
patients. Increased molecular understanding of the causal
factors will therefore be beneficial in both diseases.
Very few studies have systematically evaluated the age-
dependent changes in human tissue including cartilage due
to limited availability of human cartilage tissue. These stud-
ies are particularly pertinent to cartilage because cartilage
regeneration is inefficient even in healthy young adults,
often leading to OA, even though pediatric patients
demonstrate superior cartilage repair. Recently, allogeneic
juvenile cartilage (from donors below 13 years of age) has
even been successfully utilized for repair of focal cartilage
defects. Upon phenotypic and functional characterization
of juvenile and adult chondrocytes, it was found that
juvenile chondrocytes demonstrate increased cell pro-
liferation and extracellular matrix (ECM) generation
as compared to the adult chondrocytes [1]. The molecular
factors responsible for these functional differences that de-
fine the regenerative capacity of juvenile and adult chon-
drocytes have, however, not been characterized.
Another key question that remains unanswered is how
age-related changes modulate the cell and tissue-specific
response to inflammation. Inflammaging, i.e. systemic
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upregulation of inflammatory cues with aging is a well-
documented phenomenon. For example, plasma levels of
the pro-inflammatory cytokine, interleukin-6 (IL-6) are
low in young adults and begin to increase in healthy
people at about 50–60 years of age [2]. Inflammaging is
associated with many forms of age-related pathological
conditions, such as neurodegeneration, atherosclerosis,
metabolic syndrome, diabetes mellitus and conditions af-
fecting the musculoskeletal system (i.e. osteoporosis, OA
and RA) [3, 4]. However, it remains unclear whether the
age-related changes in tissues render them increasingly
susceptible to the inflammaging cues, thereby leading to
increased inflammation-mediated damage in aging tissues.
To address the effects of age-related changes in
cartilage regeneration and degeneration, we have re-
cently performed genome-wide gene expression profiling
of juvenile and adult chondrocytes [5]. Striking pheno-
typic and functional differences have been reported
between juvenile and adult human chondrocytes, dem-
onstrating the characteristic functional differences such
as increased ECM production by the juvenile chondro-
cytes compared to adult chondrocytes [6, 7]. In order to
dissect the underlying biological differences that lead to
the observed increased regenerative capability of juvenile
chondrocytes [5, 7], we have compared the molecular
differences between the juvenile and adult articular
chondrocytes by utilizing exon microarrays to determine
their global gene expression profiles [5].
Multiple previous studies have identified cell-surface clus-
ter of differentiation (CD) molecules including CD44 (the
hyaluron receptor), CD90 (Thy 1) and CD49 (alpha
integrins) to play critical roles in and be markers of the
chondrogenic capacity of chondrocytes [8–11]. Among ap-
proximately 600 factors that were differentially upregulated
in juvenile chondrocytes, our studies identified CD24 to be
highly enriched in juvenile chondrocytes with expression be-
ing lost with age such that the adult chondrocytes only dem-
onstrate a modest expression. CD24 is a small, heavily
glycosylated and glycosyl-phosphatidylinositol (GPI)-an-
chored cell-surface protein that is a co-stimulator for
antigen-specific T cell responses and a differentiation marker
for B cells [12, 13]. Importantly, polymorphisms of human
CD24 are associated with risk and progression of several
autoimmune diseases, multiple sclerosis and RA [14–17]. In
this study, we provide evidence for a novel role for CD24 in
cartilage function whereby it can negatively modulate NFκB
activity and hence the response to inflammatory cues.
Methods
Chondrocyte isolation and culture
Four individual juvenile and four individual adult samples
were analyzed in the study. The juvenile articular chondro-
cytes (from a 24-week old fetus (designated as J1), a 6-year-
old child (J2), and a 6-month-old (J3) and an 18-month
(J4) infant) were purchased from Lonza (Clonetics™, Lonza
Walkersville, Inc.). These primary chondrocytes (four bio-
logical samples) were then thawed, expanded for 5–7 days
as high-density monolayers and utilized for experiments.
Adult articular chondrocytes were harvested from
grossly normal pieces of cartilage discarded during
notchplasty or debridement from patients with no prior
history of OA under protocols approved by the human
subjects Institutional Review Board of Stanford University.
The four adult samples utilized in the study were from a
female 27-year-old (A1), a male 35-year-old (A2), a male
18-year-old (A3), and a female 39-year-old (A4) individual.
The cartilage pieces were dissected and the chondrocytes
were dissociated from the matrix as described previously
[18]. All chondrocytes were cultured in high-density
monolayers for limited passages (under four passages), as
described previously [5, 7].
Five different batches of human induced pluripotent
stem cell-derived chondrocytes (hiChondrocytes) were
derived by differentiation of human induced pluripotent
stem cells (hiPSC) as previously described and character-
ized [10]. Five different batches were utilized to ensure
reproducibility. The hiChondrocytes were cultured for up
to four passages and used to test for CD24 expression.
Flow cytometry
Cells were dissociated to a single-cell suspension using
TrypLE (Life Technologies) and fixed in BD Cytofix
buffer (BD Biosciences) for 20 minutes at room
temperature. For permeabilization, cells were washed
and incubated with BD Permeabilization/Wash buffer
(BD Biosciences) at 1 × 107 cells per 1 mL for 10 minutes.
Cells were stained by incubating with anti-human CD24-
PE (BD Biosciences) for 30 minutes. The antibody was
diluted according to manufacturer’s instruction. Stained
cells were scanned using an LSRII flow cytometer and
analyzed with FlowJo software.
Quantitative real-time PCR
RNA was isolated with the RNeasy kit. First-strand
cDNA was primed with oligo (dT) primers and qPCR
was performed with Taqman primer sets from Applied
Biosystems (Foster City, CA). Relative expression levels
were normalized to glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and ribosomal 18S RNA. Then
expression levels were calculated using the method 2 −
Δ cycle threshold (Ct) [19].
Immunohistochemical analysis
Adult chondrocytes tissue were fixed in 4% paraformal-
dehyde (Sigma) then mounted with paraffin. Tissue
sections were de-paraffinized with 100%, 90% and 70%
ethanol and permeabilized in cold methanol (Sigma).
After blocking in PBS containing 1% BSA, tissue
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sections were incubated overnight with primary antibody
(anti-CD24, 1:100, BD). The following day cells were
washed in PBS and incubated for 1 hour in secondary
antibody (Alexa 594 goat anti-rabbit 1:250, Invitrogen)
and cellular DNA was counterstained with 4',6-diami-
dino-2-phenylindole (DAPI) (Life Technologies).
IL-1ß treatment
Chondrocytes were plated at 5 × 105 cells per well in du-
plicates in 6-well plates. After 24 hours, cells were
treated with control or IL-1ß (10 ng/mL) in complete
media for 2 days.
ShCD24 lentiviral preparation and infection
HEK293FT cells were plated at a density of 6 × 106 cells
per T225 flask and incubated overnight. Cells were
transfected with 7.5 μg of VSV-G, 5.7 μg of TAT, 7.5 μg
of Rev, 30 μg of Gag/Pol and 15 μg of shCD24 lentiviral
plasmid (Sigma) with Lipofectamine. The supernatant
was collected 48 hours after transfection and filtered
through a 0.45-μm filter. Following spinning at 17,100
rpm for 2 hours 20 minutes, the viral pellet was resus-
pended to make × 100 stock solutions. To knock down
CD24 expression, chondrocytes were seeded at 5 × 104
cells per well of a 6-well dish a day before transduction.
The medium was replaced with 100 multiplicity of infec-
tion (MOI) virus-containing supernatant supplemented
with 8 μg/mL polybrene, and incubated for 24 hours. The
transduced chondrocytes were then cultured in chondro-
cyte medium and we evaluated the reduction in CD24
using real-time quantitative PCR.
NFκB luciferase assay
Chondrocytes (3 × 105/well) were subjected to either
shNTC or shCD24 infection with or without IL-1ß (10
ng/mL). Cells were transfected with pNFκB-Luc (Agilent
Technologies, Santa Clara, CA, USA) and pFC-MEKK as
a positive control plasmid by using Fugene 6 (Promega,
Madison, WI, USA) and after 24 hours, cells were
assayed using the Bright-Glo Luciferase Assay System
(Promega) with a luminometer. In order to account for
any differences in transfection efficiency, the PathDetect
reporting system (Agilent Technologies, Santa Clara, C,
USA) utilized an unrelated reporter pFC-MEKK contain-
ing a MEKK kinase from the constitutive cytomegalovirus
(CMV) promoter responsible for activating luciferase
transcription as a positive control. We used 1ug/uL of
pCIS-CK negative control plasmid containing the lucifer-
ase reporter gene and no cis-acting DNA elements as a
negative control. Cells with or without CD24 (i.e. non-
target and shCD24-infected cells, respectively) were trans-
fected with either 1 ug/uL of pNFκB-Luc (experimental)
or 1 ug/uL of pFC-MEKK, i.e the positive control. The
luciferase activity for the positive control was utilized to
normalize the pNFκB-Luc activity.
Statistical analyses
Data are reported as the mean ± standard error of the
mean (SEM) and followed the normal distribution of
independent experiments, which were done at least
three times. Statistical analysis was performed using the
two-tailed Student’s t test and one-way analysis of vari-
ance (ANOVA) followed by the Bonferroni’s test for
multiple-comparisons. P values less than 0.01 were con-
sidered significant (details in Additional file 1).
Results
CD24 expression is high in juvenile chondrocytes
compared to adult chondrocytes
The juvenile and adult samples used in the previous and
present study were characterized in detail for chondro-
genic gene expression (high Sox9 and Col2a1 expres-
sion), lack of fibrocartilage or dedifferentiation markers
(no increase in Col1a or Col10a1 expression) and the
characteristic functional differences between the adult
and juvenile chondrocytes, such as higher proliferation
and ECM production as described previously [7].
Among the identified factors, the cell-surface receptor
CD24 showed 8-fold to 10-fold increased expression in
juvenile chondrocytes as compared to the adult chondro-
cytes. To validate the differential enrichment of CD24 in
juvenile chondrocytes, we examined CD24 expression at a
transcript level by quantitative PCR and at a single cell
protein level utilizing FACS analyses (Fig. 1a). Gene
expression analyses on juvenile and adult articular chon-
drocytes from four different donors each (see “Methods”)
confirmed an 8-fold to 10-fold increase in CD24 expres-
sion in the juvenile chondrocytes compared to the adult
chondrocytes (Fig. 1a).
Juvenile (n = 2 donors) and adult chondrocytes (n = 2
donors) were further utilized for the single cell flow
cytometry analyses. FACS analyses demonstrated that
the juvenile chondrocytes consisted of a uniformly
CD24high population (81–92%). The majority of the adult
chondrocytes on the other hand showed a lower level of
CD24 expression with a smaller population (30 − 34%)
being CD24high (Fig. 1b). Supporting these observations
in isolated chondrocytes, immunostaining for CD24 in
dissected adult cartilage slices showed CD24 expression
but not in all the chondrocytes (Figure S1, see Additional
file 2). Collectively, these data confirmed that CD24 is a
cell surface receptor enriched in juvenile chondrocytes as
compared to adult chondrocytes.
As CD24 appeared to mark juvenile chondrocytes, we
next assessed CD24 expression in the hiPSC-derived
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chondrocytes (hiChondrocytes). We have previously
established methods to differentiate hiPSC into articular-
like chondrocytes (hiChondrocytes) and characterized
the chondrogenic phenotype of the hiChondrocytes in
terms of gene and protein expression and their ability to
engineer cartilage in vitro and in vivo [10]. We therefore
hypothesized that these hiChondrocytes will mimic
developmentally younger chondrocytes and may have
enriched levels of CD24. To test this hypothesis, we
investigated CD24 expression during differentiation of
hiPSC to chondrocytes in vitro at days 4, 7, 14, 18 and
20 after the initiation of differentiation. Interestingly,
although hiPSC demonstrated low levels of CD24 as has
been previously reported [20], the intensity of CD24
expression gradually increased during chondrogenic
differentiation with the hiChondrocytes consisting of a
uniformly CD24high population after differentiation and
early cell passages (Fig. 1c). Upon comparing CD24 gene
expression in five biological replicates of independently
derived hiChondrocytes to adult chondrocytes, a 10-fold
to 18-fold increase was consistently observed demonstrat-
ing that the hiChondrocytes were similar to the neonatal/
juvenile chondrocytes in terms of CD24 expression
(Fig. 1d). Collectively, these observations confirmed that
CD24 is a cell surface receptor enriched in neonatal and
juvenile chondrocytes as compared to adult chondrocytes.
Differential inflammatory response in juvenile and adult
chondrocytes
As CD24 has been shown to modulate innate immunity in
immune cells [21], we questioned whether differential
expression of CD24 in juvenile and adult chondrocytes will
affect the response to pro-inflammatory cues. As IL-1ß
plays a major role in inflammation in cartilage, we
a b
c d
Fig. 1 a Gene expression for CD24 is higher in juvenile chondrocytes (J1–J4: donor ages 24 weeks, 6 years, 6 months and 18 months) as compared to adult
chondrocytes (A1− A4; donor age 18 (male), 35 (male), 27 (female) and 39 (female) years); *p< 0.01. b Flow cytometry analyses (right) show a higher
percentage of CD24-positive cells in juvenile chondrocyte populations (J1, J2), 92% and 81%, respectively, as compared to 30% and 34% in
adult chondrocytes (A1, A2). c CD24 expression is gradually increased during chondrocyte differentiation from human induced pluripotent
stem cells (iPSCs). d Human induced pluripotent stem cell-derived chondrocytes (hiChondrocytes) (hiC1–hiC5) expresses CD24 to a greater
extent than adult chondrocytes. Gene expression is relative to adult articular chondrocytes (AC)1 in the absence of IL-1ß for each respective
gene; *p < 0.01
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determined the response to IL-1ß treatment in CD24high
chondrocytes (juvenile chondrocytes) and CD24low chon-
drocytes (adult chondrocytes). Upon IL-1ß treatment (0 or
10 ng/mL dose) of chondrocytes for 48 hours, we observed
that the expression of inflammatory genes (CCL2 and IL-6)
was upregulated in both chondrocyte types - juvenile
and adult chondrocytes (Fig. 2 and Figure S2, see
Additional file 2). However, there was significantly greater
upregulation of both CCL2 and IL-6 in the CD24low adult
chondrocytes as compared to the CD24high juvenile chon-
drocytes (Fig. 2a and Additional file 2: Figure S2).
Similarly, upon testing a few catabolic genes, we ob-
served significantly greater upregulation of MMP3 and
ADAMTS4 in the CD24low adult chondrocytes as com-
pared to the juvenile CD24high chondrocytes (Fig. 2b).
In contrast, chondrogenic gene expression (COL2A and
SOX9) was significantly decreased only in the CD24low
adult chondrocytes in response to IL-1ß treatment
while the CD24high juvenile chondrocytes were resistant
and maintained the chondrogenic gene expression
(Fig. 2c). Overall, the CD24low chondrocytes had greater
susceptibility to inflammatory cytokines.
Loss of CD24 increases inflammatory response in
chondrocytes
In order to further understand the effect of CD24 expres-
sion on the inflammatory and chondrogenic genes, we
next investigated the effect of CD24 loss in the juvenile
and adult chondrocytes. We firstly tested a set of five short
hairpin (sh)RNAs and identified three independent
shRNAs (sh1, 2 and 3; see “Methods”) that consistently
showed an 80% or greater knockdown for CD24 at the
gene and protein levels (Fig. 3 and Additional file 2).
Real-time quantitative PCR was utilized to determine
Fig. 2 Differential inflammatory response in juvenile (J1, J2) and adult chondrocytes (A1, A2) upon IL-1ß stimulation (10 ng/mL) upon gene expression
of inflammatory genes (IL-6 and CCL2) (a), catabolic genes (MMP3 and ADAMTS4) (b) and chondrocyte regulatory genes (COL2A and SOX9) (c); *p < 0.01.
Gene expression is relative to control in the absence of IL-1ß for each respective gene
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the mRNA levels and single-cell FACS analyses were
used to confirm CD24 expression at the protein
level. A non-target control shRNA was used along
with the CD24 specific shRNA. Upon causing shRNA-
mediated loss of CD24 in chondrocytes, we observed up-
regulation of the inflammatory genes IL-6 and CCL2 in
juvenile and adult chondrocytes even in the absence of
any stimulation with any pro-inflammatory cytokines
(Fig. 3a). A similar increase was observed in the expres-
sion of catabolic genes, MMP3 and ADAMTS4, upon loss
of CD24; however, this increase was modest across the
different chondrocytes (Fig. 3b). In contrast, loss of CD24
alone (that happens during normal aging) does not alter
expression of the chondrogenic genes, COL2A and SOX9
(Fig. 3c).
Next, we assessed the effect of loss of CD24 in chon-
drocytes upon exposure to pro-inflammatory cytokines.
Chondrocytes transduced with either the non-target
control or CD24-specific shRNA were treated with IL-
1ß treatment (0 or 10 ng/mL dose) for 48 hours. Gene
expression of inflammatory (IL-6 and CCL2), catabolic
(MMP3 and ADAMTS4) and chondrogenic (COL2A
and SOX9) genes were then assayed using quantitative
PCR. Loss of CD24 in combination with IL-1ß in chondro-
cytes enhanced inflammatory and catabolic gene expres-
sion, with significantly higher upregulation of IL-6, CCL2,
MMP3 and ADAMTS4 in juvenile chondrocytes (Fig. 4).
For adult chondrocytes that already had a small subset of
cells expressing CD24, loss of CD24 further increased up-
regulation of CCL2 and ADAMTS4 significantly but not of
Fig. 3 Loss of CD24 increases inflammatory gene expresson (a), and catabolic gene expression (b), but not chondrogenic gene expression (c), in
both juvenile chondrocytes (J1, J2) and adult chondrocytes (A1, A2); *p < 0.01. Gene expression is relative to control short hairpin RNA (shNTC) for
each respective gene
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IL6 or MMP3 in the presence of IL-1ß (Fig. 4). Interest-
ingly, loss of CD24 rendered the juvenile chondrocytes sus-
ceptible to dedifferentiation in the presence of IL-1ß. In
the presence of CD24 however, these chondrocytes were
protected from the IL-1ß- mediated loss of COL2A and
SOX9 (see Additional file 2: Figure S4).
CD24 inhibits NFκB activation in chondrocytes
The NFκB pathway is known to regulate expression of
inflammatory and catabolic genes in OA. Previous
studies have shown that CD24 signaling can inhibit
NFκB activation in the immune system [21], therefore,
we tested whether CD24 expression modulates NFκB ac-
tivity in chondrocytes as well. NFκB activity was examined
using NFκB reporter luciferase assay in the absence and
presence of CD24. Upon transfection of NFκB-responsive
luciferase construct in chondrocytes, we observed signifi-
cantly higher relative luminescence in adult chondrocytes
compared to juvenile chondrocytes in the absence and
presence of IL-1ß (10 ng/mL) (Fig. 5a). Next, chondrocytes
Fig. 4 Loss of CD24 augments inflammatory response in the presence of IL-1ß (10 ng/mL). Gene expression for IL6 (a), CCL2 (b), MMP3 (c) and
ADAMTS4 (d) in juvenile and adult chondrocytes upon control and shCD24 transduction in the absence and presence of IL-1ß; *p< 0.01 and †p< 0.01).
shNTC control short hairpin RNA
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transduced with control shRNA (shNTC) or CD24 shRNA,
were treated with IL-1ß (0 or 10 ng/mL dose) for 48 hours.
After 24 hours of treatment, the NFκB-responsive lucifer-
ase construct was transfected in the chondrocytes, and
assayed after another 24 hours (Fig. 5b). Increased relative
luminescence, representing NFκB activity, was observed
upon loss of CD24, which increased significantly upon IL-
1ß treatment in all chondrocytes (Fig. 5b).
Discussion
Juvenile chondrocytes (from donors under 13 years of
age) have emerged in recent years as an attractive cell
source for cartilage regeneration and tissue engineering.
Differences between the juvenile and adult chondrocytes
include increased proliferation and ECM generation in
juvenile chondrocytes [22]. In addition, transplantation of
allogeneic juvenile chondrocytes without any adverse ef-
fects and their inability to stimulate immune cells has sug-
gests they are immune-privileged [1, 23]. In the present
studies, we have additionally characterized hiPSC-derived
chondrocytes (hiChondrocytes) that are a model for em-
bryonic neonatal chondrocytes.
In studying hiChondrocytes (neonatal), juvenile chon-
drocytes (<13 years old donors) and adult chondrocytes
(from donors aged 18–35 years), we are able to study a
spectrum of early human cartilage development and aging,
especially the response of these chondrocyte subsets to in-
flammatory cues. Interestingly, our studies demonstrate
that juvenile chondrocytes and adult chondrocytes have a
differential response to pro-inflammatory cues exemplified
by IL-1ß. Upon IL-1ß stimulation, there was a greater
upregulation of both inflammatory genes (such as CCL2
and IL-6) and catabolic genes (MMP3 and ADAMTS4) in
adult chondrocytes compared to juvenile chondrocytes,
revealing that the adult chondrocytes are more susceptible
to inflammatory cues. In addition, the adult chondrocytes
are more prone to dedifferentiation than the younger
chondrocytes, as they had rapid loss of expression of
chondrogenic genes, COL2A and SOX9, in the presence of
IL-1ß. These results indicate that the juvenile chondro-
cytes are protected against inflammation and dedifferenti-
ation and that this protection is gradually lost with aging
(Fig. 6). Therefore, our studies highlight the fact that
CD24high juvenile articular chondrocytes with low im-
mune responsiveness may have a distinctive advantage for
cartilage repair especially in the highly inflammatory end-
stage environment in RA and OA. In further studies, we
would like to extend this characterization to chondrocytes
from donors aged 40–60 years to discern whether the
responsiveness to inflammatory cytokines is increased
further with aging.
A central revelation of our studies is that CD24 is a novel
molecular factor enriched in juvenile chondrocytes and
regulates response towards inflammatory cues. Import-
antly, clinical studies have reported that the polymor-
phisms of human CD24 are associated with risk and
progression of several autoimmune diseases, multiple scler-
osis and rheumatoid arthritis (RA) [14–17]. In addition,
CD24 expression and its prognostic significance have been
reported for many types of cancer including breast,
colorectal, gastric, lung, ovarian and pancreatic cancers,
supporting CD24 as a diagnostic marker of cancer [24–27].
Although the clinical significance and function of CD24 in
various diseases have been frequently reported, the regula-
tory and signaling mechanisms of CD24 are only begin-
ning to be understood. CD24 does not contain a cytosolic
domain, hence it needs to associate with and signal
through another cell-surface receptor. In innate immune
cells, CD24 has been shown to associate with Siglec-G, a
member of the sialic acid-binding immunoglobulin-like
Fig. 5 CD24 regulates nuclear factor kappa-activated B cell (NFκB) activity. a Using an NFκB-responsive luciferase construct, higher relative luminescence
denoting higher NFκB activity is observed in adult chondrocytes (AC) compared to juvenile chondrocytes (JC) in the absence and presence of
IL-1ß. b Loss of CD24 increases NFκB activity in the absence and presence of IL-1ß; *p < 0.01. shNTC control short hairpin RNA
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lectin family in response to endogenous damage signals
like high mobility group box 1 (HMGB1), heat shock pro-
tein 70 (HSP70) and heat shock protein 90 (HSP90) that
are a part of the damage-associated molecular patterns
(DAMP). Siglec-G contains cytosolic domains that inhibit
NFκB, such that a loss of CD24 or Siglec-G can aberrantly
activate NFκB. Both CD24-deficient and Siglec-G deficient
mice, although viable, have been reported to demonstrate
an intense response to induced inflammation in the liver,
leading to acute and lethal liver damage [21, 28]. Blocking
CD24 through soluble CD24, consisting of the extracellu-
lar portion of murine CD24 and human IgG1 Fc amelio-
rated the clinical symptom of experimental autoimmune
disease, the mouse model of multiple sclerosis [29].
In the present studies, we demonstrate that the presence
of high CD24 in the CD24high juvenile chondrocyte popu-
lations keeps NFκB activation in check while a higher
NFκB activity is observed in CD24low adult chondrocytes.
Silencing experiments that downregulated CD24 expres-
sion validated that CD24 is a negative modulator of NFκB
activity. The higher NFκB activity in adult chondrocytes is
accompanied by higher baseline expression of CCL2 and
IL-6, and upon cytokine stimulation it leads to aug-
mented upregulation of inflammatory and catabolic
genes along with rapid downregulation of chondrogenic
genes (Fig. 6). Therefore, we have identified CD24 to be
a novel modulator of the downstream NFκB pathway in
chondrocytes. While the function of CD24 in immune cells
has been in focus in autoimmune diseases and RA, our
studies provide the important insight that changes in CD24
expression in cartilage additionally modulate the cartilage
response towards inflammation in cartilage degenerative dis-
eases. In future studies, we will explore the cartilage-specific
CD24 cofactors (the Siglec family members for example)
that interact with the components of the NFκB pathway and
the mechanisms that ultimately lead to NFκB inhibition.
Conclusions
Our studies provide new insights into the molecular mech-
anisms that underlie cartilage response to inflammatory
cues during development, aging and disease. Decreased
CD24 expression in chondrocytes during development and
aging modulates NFκB activation and the intrinsic re-
sponse of the chondrocytes to environmental inflamma-
tion. Inhibition of inflammatory modulators such as CD24
can also potentially constitute novel therapeutic strategies
for cartilage degenerative diseases.
Additional files
Additional file 1: Supplemental methods. (DOCX 73 kb)
Additional file 2: Figure S1. Immunofluorescence staining for CD24 in
two independent adult cartilage tissues, red CD24-PE and blue DAPI (scale
bar 100 um). Figure S2. Differential inflammatory response demonstrated
in individual juvenile and adult chondrocytes (J1, J2, A1, A2) upon IL-1ß
stimulation (10 ng/mL) to show the reproducibility of response. Gene
Fig. 6 Schematic overview of the chondroprotective role of CD24 in cartilage
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expression of inflammatory genes (IL6 and CCL2) (A) and catabolic genes
(MMP3 and ADAMTS4) and chondrocyte regulatory genes (COL2A and
SOX9) (B) in the absence and presence of IL-1ß. Gene expression is relative
to J1 in the absence of IL-1ß for each respective gene. Figure S3. A CD24
gene expression upon transduction of shRNAs against CD24 (sh1–sh5) in
chondrocytes. B CD24 expression upon shCD24 knockdown (sh1, sh2) in
juvenile (J1, J2) and adult chondrocytes (A1, A2). C Flow cytometry analyses
confirmed reduction in CD24-positive cells in juvenile and adult chondrocyte
populations upon shCD24 transduction. Figure S4. Loss of CD24 synergistically
enhances downregulation of chondrogenic genes (A) Sox9 and (B) Col2a1, in
the presence of IL-1ß (10 ng/mL) in juvenile and adult chondrocytes; *p< 0.01.
(PDF 757 kb)
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